generation run 2026-05-09
60 min completedmodel pipeline-v5plan not recordedrun/21eadb04…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
- taper_confidence_medium
- structural_inference
- safety_critical
Reproduce
- inputs
- 44 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
19 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | PubChem | bromazepam | 1 | 1 | Core chemical identity verification |
| 2 | PubMed | bromazepam pharmacology mechanism GABA receptor | 6 | 4 | Directly relevant to pharmacology and GABA-A mechanism |
| 3 | ClinicalTrials.gov | bromazepam anxiety | 4 | 0 | No trials specifically on bromazepam found; broader benzodiazepine context only |
| 4 | PubMed | bromazepam overdose toxicity adverse effects case report | 7 | 5 | Overdose and toxicity case reports for safety section |
| 5 | PubMed | bromazepam clinical trial anxiety treatment efficacy | 10 | 6 | Clinical trial data and therapeutic efficacy studies for bromazepam |
| 6 | PubMed | bromazepam pharmacokinetics bioavailability metabolism human | 10 | 8 | Core pharmacokinetic data for bromazepam |
| 7 | OpenAlex | bromazepam benzodiazepine | 10 | 5 | Landmark benzodiazepine papers relevant to bromazepam context |
| 8 | OpenAlex | bromazepam pharmacokinetics half-life | 8 | 3 | Relevant landmark papers on BZD pharmacokinetics |
| 9 | WebSearch | bromazepam pharmacokinetics half-life protein binding volume distribution | 10 | 2 | Supplementary PK data; will defer to published PMID 2882883 for definitive values |
| 10 | PubMed | bromazepam elderly hepatic impairment pharmacokinetics clearance | 1 | 1 | Core human PK study already selected |
| 11 | PubMed (PMID 2882883) | Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol | 1 | 1 | Primary source for bromazepam PK parameters |
| 12 | WebSearch | bromazepam history discovery Roche synthesis 1960s development | 10 | 1 | Historical context for discovery narrative |
| 13 | PubMed · absence | bromazepam half-life plasma protein binding | 0 | 0 | Redirected to web search |
| 14 | WebSearch/GOV.UK | bromazepam UK schedule misuse act Canada controlled drug classification | 10 | 1 | Legal status data for UK and international scheduling |
| 15 | PubMed (PMID 24007886) | History of benzodiazepines | 1 | 1 | Historical context for BZD class including bromazepam |
| 16 | PubMed | benzodiazepine dependence abuse chronic long-term effects | 3 | 1 | Tolerance mechanism (GABA-A downregulation + glutamatergic sensitization) and management strategies |
| 17 | PubMed | bromazepam generalized anxiety disorder Hamilton anxiety scale | 4 | 3 | Core clinical efficacy data for generalized anxiety |
| 18 | WebSearch/TGA Australia | bromazepam Lexotan Australia Schedule 4 TGA | 10 | 2 | Australian legal classification confirmed |
| 19 | Multiple | bromazepam half-life discrepancy across sources | 3 | 1 | Flagging PK half-life discrepancy for generation agent |
174 claims by section — every cited sentence, checked against its source
safety48 · 4 ok
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Femoral blood levels of 2,500 µg/L were found in a fatal multidrug overdose (polypharmacy: tramadol, propranolol, zopiclone, citalopram)partially supported
Zopiclone detected at 1,200 mcg/L in femoral blood at toxic concentrations alongside tramadol, propranolol, bromazepam, and citalopram. ftd.0000000000001150
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — not_supportednot supportedworking →
Claim in safety — inconclusiveinconclusiveworking →
Repeated benzodiazepine use produces tolerance via two complementary mechanisms: (1) downregulation and uncoupling of GABA-A receptor subunits, particularly α1 and γ₂, reducing allosteric potentiation efficacy; (2) compensatory upregulation and sensitization of excitatory glutamatergic (nmda-receptor) systems, shifting the excitatory-inhibitory balance. Cross-tolerance exists between all benzodiazepines and between benzodiazepines and alcohol (class-level evidence).supported
BZDs act as positive allosteric modulators of GABA-A; prolonged use causes tolerance via GABA-A subunit downregulation and compensatory glutamatergic sensitization; management requires gradual tapering with long-acting BZD ijms27031430
Claim in safety — not_supportednot supportedworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Clinical management requires gradual tapering, typically 10–25% dose reduction per 1–2 weeks, sometimes with substitution to a longer-acting benzodiazepine.supported
management requires gradual tapering with long-acting BZD ijms27031430
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Fatal combined overdose cases involving tramadol and bromazepam have been documented.supported
Fatal multidrug overdose case. Zopiclone detected at 1,200 mcg/L in femoral blood at toxic concentrations alongside tramadol, propranolol, bromazepam, and citalopram. ftd.0000000000001150
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
pharmacology36 · 0 ok
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
clinical-evidence19 · 1 ok
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Bertolino et al. (1989) compared bromazepam 3 mg to etizolam and alprazolam in a 45-patient GAD trial; all three compounds showed equivalent anxiolytic efficacy, though etizolam demonstrated greater antidepressant effect.supported
45 patients, double-blind comparison of etizolam 0.5mg, alprazolam 0.5mg, and bromazepam 3mg twice daily. Equivalent anxiolytic activity; etizolam showed progressive increase in effect over 4 weeks and more antidepressant activity. pmid:2572494
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
pharmacokinetic-detail17 · 0 ok
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
summary14 · 2 ok
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Hoffmann-La Roche under the code Ro 5-3350 as part of the systematic benzodiazepine program that followed Leo Sternbach's discovery of chlordiazepoxide in 1955, bromazepam entered clinical use circa 1974partially supported
In 1955, Hoffmann-La Roche chemist Leo Sternbach serendipitously identified the first benzodiazepine, chlordiazepoxide. tcp.n.2013.538
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Acute lethality of bromazepam alone is low — a class feature of benzodiazepines — but fatalities occur reliably in polydrug contexts involving alcohol, opioids, or other CNS depressants. Physical dependence develops with repeated use via GABA-A receptor subunit downregulation and compensatory glutamatergic sensitization; abrupt cessation after chronic use risks seizures and status epilepticussupported
prolonged use causes tolerance via GABA-A subunit downregulation and compensatory glutamatergic sensitization; management requires gradual tapering with long-acting BZD ijms27031430
Claim in summary — inconclusiveinconclusiveworking →
comparative-pharmacology12 · 1 ok
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Etizolam demonstrated superior antidepressant effect, while anxiolytic potencies were indistinguishable among the three compounds.supported
Equivalent anxiolytic activity; etizolam showed progressive increase in effect over 4 weeks and more antidepressant activity. pmid:2572494
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
history10 · 1 ok
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Hoffmann-La Roche Ltd. that followed Leo Sternbach's serendipitous discovery of chlordiazepoxide in 1955 and the subsequent development of diazepam (Valium) in 1963supported
In 1955, Hoffmann-La Roche chemist Leo Sternbach serendipitously identified the first benzodiazepine, chlordiazepoxide. Valium (diazepam) followed in 1963. tcp.n.2013.538
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
neuroscience10 · 1 ok
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — not_supportednot supportedworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Chronic benzodiazepine exposure produces maladaptive neuroplasticity: downregulation of α1 and γ₂ GABA-A receptor subunits with compensatory upregulation and sensitization of excitatory glutamatergic (nmda-receptor) systemssupported
prolonged use causes tolerance via GABA-A subunit downregulation and compensatory glutamatergic sensitization ijms27031430